For: | Liu JB, Zhang YX, Zhou SH, Shi MX, Cai J, Liu Y, Chen KP, Qiang FL. CpG island methylator phenotype in plasma is associated with hepatocellular carcinoma prognosis. World J Gastroenterol 2011; 17(42): 4718-4724 [PMID: 22180715 DOI: 10.3748/wjg.v17.i42.4718] |
---|---|
URL: | https://www.wjgnet.com/1007-9327/full/v17/i42/4718.htm |
Number | Citing Articles |
1 |
Yingjie Wang, Hongyu Liu, Mengsha Zhang, Jing Xu, Liuxian Zheng, Pengpeng Liu, Jingyao Chen, Hongyu Liu, Chong Chen. Epigenetic reprogramming in gastrointestinal cancer: biology and translational perspectives. MedComm 2024; 5(9) doi: 10.1002/mco2.670
|
2 |
Lin Su, Jiawen Bu, Jiahui Yu, Mila Jin, Guanliang Meng, Xudong Zhu. Comprehensive review and updated analysis of DNA methylation in hepatocellular carcinoma: From basic research to clinical application. Clinical and Translational Medicine 2024; 14(11) doi: 10.1002/ctm2.70066
|
3 |
Ying-Hsiu Su, Selena Y Lin, Wei Song, Surbhi Jain. DNA markers in molecular diagnostics for hepatocellular carcinoma. Expert Review of Molecular Diagnostics 2014; 14(7): 803 doi: 10.1586/14737159.2014.946908
|
4 |
Steffen Zopf, Matthias Ocker, Daniel Neureiter, Beate Alinger, Susanne Gahr, Markus F Neurath, Pietro Di Fazio. Inhibition of DNA methyltransferase activity and expression by treatment with the pan-deacetylase inhibitor panobinostat in hepatocellular carcinoma cell lines. BMC Cancer 2012; 12(1) doi: 10.1186/1471-2407-12-386
|
5 |
Laura A.E. Hughes, Veerle Melotte, Joachim de Schrijver, Michiel de Maat, Vincent T.H.B.M. Smit, Judith V.M.G. Bovée, Pim J. French, Piet A. van den Brandt, Leo J. Schouten, Tim de Meyer, Wim van Criekinge, Nita Ahuja, James G. Herman, Matty P. Weijenberg, Manon van Engeland. The CpG Island Methylator Phenotype: What's in a Name?. Cancer Research 2013; 73(19): 5858 doi: 10.1158/0008-5472.CAN-12-4306
|
6 |
Way-Champ Mah, Caroline GL Lee. DNA methylation: potential biomarker in Hepatocellular Carcinoma. Biomarker Research 2014; 2(1) doi: 10.1186/2050-7771-2-5
|
7 |
Abdel-Rahman N. Zekri, Abeer A. Bahnassy, Mona S. Abdellateif. Hepatitis C - From Infection to Cure. 2018; doi: 10.5772/intechopen.76763
|
8 |
Noah X. Tocci, Chase J. Wehrle, Keyue Sun, Chunbao Jiao, Hanna Hong, Abby Gross, Erlind Allkushi, Melis Uysal, Maureen Whitsett Linganna, Katheryn Stackhouse, Koji Hashimoto, Andrea Schlegel, R. Matthew Walsh, Charles Miller, David C. H. Kwon, Federico Aucejo. Circulating tumor DNA in management of primary liver malignancy: A review of the literature and future directions. Journal of Surgical Oncology 2024; doi: 10.1002/jso.27825
|
9 |
I. F. Kustova, A. S. Makarova, N. L. Lazarevich. Potential of the use of methylation biomarkers for diagnostics and prognosis of hepatocellular carcinoma in liquid biopsy. Advances in molecular oncology 2019; 5(4): 8 doi: 10.17650/2313-805X-2018-5-4-8-19
|
10 |
Jian Zhou, Ying-Hong Shi, Jia Fan. Circulating Cell-Free Nucleic Acids: Promising Biomarkers of Hepatocellular Carcinoma. Seminars in Oncology 2012; 39(4): 440 doi: 10.1053/j.seminoncol.2012.05.013
|
11 |
Brendan Miller, Francisco Sánchez-Vega, Laura Elnitski. The Emergence of Pan-Cancer CIMP and Its Elusive Interpretation. Biomolecules 2016; 6(4): 45 doi: 10.3390/biom6040045
|
12 |
ZHENSHENG DAI, YUELING JIN. Promoter methylation of the DLC-1 gene and its inhibitory effect on human colon cancer. Oncology Reports 2013; 30(3): 1511 doi: 10.3892/or.2013.2551
|
13 |
A. Sharma, E. Abdelfatah, M. Al Eissa, N. Ahuja. Medical Epigenetics. 2016; : 177 doi: 10.1016/B978-0-12-803239-8.00011-9
|
14 |
Yujin Hoshida, Agrin Moeini, Clara Alsinet, Kensuke Kojima, Augusto Villanueva. Gene Signatures in the Management of Hepatocellular Carcinoma. Seminars in Oncology 2012; 39(4): 473 doi: 10.1053/j.seminoncol.2012.05.003
|
15 |
Chi Chun Wong, Weilin Li, Bertina Chan, Jun Yu. Epigenomic biomarkers for prognostication and diagnosis of gastrointestinal cancers. Seminars in Cancer Biology 2019; 55: 90 doi: 10.1016/j.semcancer.2018.04.002
|
16 |
William Matthew Puszyk, Thu Le Trinh, Sarah J Chapple, Chen Liu. Linking metabolism and epigenetic regulation in development of hepatocellular carcinoma. Laboratory Investigation 2013; 93(9): 983 doi: 10.1038/labinvest.2013.94
|
17 |
Jun Yu, Yang Xie, Mengying Li, Fenfang Zhou, Zhenyang Zhong, Yuting Liu, Feng Wang, Jian Qi. Association between SFRP promoter hypermethylation and different types of cancer: A systematic review and meta‑analysis. Oncology Letters 2019; doi: 10.3892/ol.2019.10709
|
18 |
Qian Wang, Gang Wang, Chaoxu Liu, Xianli He. Prognostic value of CpG island methylator phenotype among hepatocellular carcinoma patients: A systematic review and meta-analysis. International Journal of Surgery 2018; 54: 92 doi: 10.1016/j.ijsu.2018.04.033
|
19 |
Wenrui Ye, Stefan Siwko, Robert Y. L. Tsai. Sex and Race-Related DNA Methylation Changes in Hepatocellular Carcinoma. International Journal of Molecular Sciences 2021; 22(8): 3820 doi: 10.3390/ijms22083820
|
20 |
Xingyuan Ma, Zhe Wang, Shuaiyang Wang, Ye Tian, Bei Xie, Jing Li, Bin Ma, Linjing Li. The assessment of circulating tumor DNA associated with Wnt/β-catenin signaling pathway as a diagnostic tool for liver cancer: a systematic review and meta-analysis. Expert Review of Anticancer Therapy 2024; 24(3-4): 155 doi: 10.1080/14737140.2024.2312246
|
21 |
Faisal Saeed Khan, Ijaz Ali, Ume Kalsoom Afridi, Muhammad Ishtiaq, Rashid Mehmood. Epigenetic mechanisms regulating the development of hepatocellular carcinoma and their promise for therapeutics. Hepatology International 2017; 11(1): 45 doi: 10.1007/s12072-016-9743-4
|
22 |
Xiaoli Zhao, Feng Yang, Shuang Li, Meixia Liu, Shaoxu Ying, Xiaodong Jia, Xiaoqin Wang. CpG island methylator phenotype of myelodysplastic syndrome identified through genome‐wide profiling of DNA methylation and gene expression. British Journal of Haematology 2014; 165(5): 649 doi: 10.1111/bjh.12811
|
23 |
Ying-Hsiu Su, Amy K. Kim, Surbhi Jain. Liquid biopsies for hepatocellular carcinoma. Translational Research 2018; 201: 84 doi: 10.1016/j.trsl.2018.07.001
|
24 |
André Nogueira da Costa, Zdenko Herceg. Detection of cancer‐specific epigenomic changes in biofluids: Powerful tools in biomarker discovery and application. Molecular Oncology 2012; 6(6): 704 doi: 10.1016/j.molonc.2012.07.005
|
25 |
Masato Nakamura, Tetsuhiro Chiba, Kengo Kanayama, Hiroaki Kanzaki, Tomoko Saito, Yuko Kusakabe, Naoya Kato. Epigenetic dysregulation in hepatocellular carcinoma: an up‐to‐date review. Hepatology Research 2019; 49(1): 3 doi: 10.1111/hepr.13250
|
26 |
Katherine E. Varley, Jason Gertz, Kevin M. Bowling, Stephanie L. Parker, Timothy E. Reddy, Florencia Pauli-Behn, Marie K. Cross, Brian A. Williams, John A. Stamatoyannopoulos, Gregory E. Crawford, Devin M. Absher, Barbara J. Wold, Richard M. Myers. Dynamic DNA methylation across diverse human cell lines and tissues. Genome Research 2013; 23(3): 555 doi: 10.1101/gr.147942.112
|
27 |
Yukie Saeki, Minako Abe, Fumika Kono, Akane Nakazato, Yoshimori Ishihara, Hiroyuki Abe. DNA methylation analysis of cancer-related genes from cell-free DNA of patients with cancer. Personalized Medicine Universe 2017; 6: 4 doi: 10.1016/j.pmu.2017.04.002
|
28 |
Eri Arai, Takuya Yotani, Yae Kanai. DNA and Histone Methylation as Cancer Targets. Cancer Drug Discovery and Development 2017; : 437 doi: 10.1007/978-3-319-59786-7_16
|
29 |
BAIYING XU, YANFANG NIE, XIAOXIA LIU, SHUQIN FENG, ZHILI YANG, ZHIGANG WANG, QI ZHENG, XIAOYING LUO. Quantitative analysis of APC promoter methylation in hepatocellular carcinoma and its prognostic implications. Oncology Letters 2014; 7(5): 1683 doi: 10.3892/ol.2014.1951
|
30 |
Fatma El-shaarawy, Mai M. Abo ElAzm, Rasha H. Mohamed, Mohamed I. Radwan, Dina M. Abo-Elmatty, Eman T. Mehanna. Relation of the methylation state of RUNX3 and p16 gene promoters with hepatocellular carcinoma in Egyptian patients. Egyptian Journal of Medical Human Genetics 2022; 23(1) doi: 10.1186/s43042-022-00256-2
|
31 |
Yu-Zheng Xue, Tie-Long Wu, Yan-Min Wu, Ying-Yue Sheng, Zhe-Qiang Wei, Yu-Feng Lu, Li-Hua Yu, Jian-Ping Li, Zhao-Shen Li. DLC-1 is a candidate biomarker methylated and down-regulated in pancreatic ductal adenocarcinoma. Tumor Biology 2013; 34(5): 2857 doi: 10.1007/s13277-013-0846-4
|